List your practice on InjuredCare | Log in / Sign up

Hernia or Surgical Mesh Injuries

Hernia or Surgical Mesh Injuries

Created from both organic and inorganic materials, surgical mesh (most frequently used to repair hernias) comes in the form of a loosely woven sheet. It may be used for temporary or permanent support of tissues or organs. Surgical mesh also may be used in reconstructive surgery, including a procedure known as transvaginal pelvic organ prolapse repair, usually associated with urinary incontinence.

A temporary mesh is designed to degrade or dissolve over time, whereas the permanent form of the mesh is expected to stay in the body. Different temporary meshes dissolve over different periods of time, lasting months or even years.

Because the organic/inorganic compositions of each type of mesh differ, some are more easily integrated into the body than others. Though the implantation of surgical mesh naturally stimulates an anti-inflammatory response in the body, it may be as minimal as the formation of a type of scar tissue around the mesh, or it can lead to a dangerous chemical response that causes the body to reject the mesh.

In 2011, the U.S. Food and Drug Administration (FDA) released a notice to the public concerning the potential complications resulting from the use of surgical mesh. Among the documented adverse side effects are:

  • Allergic reactions
  • Dangerous adhesions
  • Injuries to nearby organs, nerves, or blood vessels

In response to FDA concerns, as well as a number of lawsuits, many of the manufacturers of surgical mesh have pulled their products from the market. Beginning in late 2018, the FDA required premarket approval for any mesh to be used for transvaginal pelvic organ prolapse repair. After further investigation, on April 16, 2019, the FDA ordered all makers of transvaginal surgical meshes to immediately stop their sale and distribution.

Related Articles

  • Aptivus


    Aptivus is the brand name for the HIV and AIDS medication tipranavir, which has caused some patients to experience severe liver damage and brain hemorrhaging. Aptivus was initially Read More...

  • Benicar


    Benicar, Azor, and Tribenzor are brand names for the generic blood pressure medication olmesartan medoxomil. Olmesartan was approved by the FDA in April of 2002 to treat high blood Read More...

  • Onglyza


    Onglyza was co-formulated by Bristol-Myers Squibb and AstraZeneca in 2007. On July 31, 2009, it was approved by the FDA for treatment of type-2 diabetes. Its key active ingredient, Read More...

© 2015-2022 LawConnect, Inc. All rights reserved.